126 related articles for article (PubMed ID: 26235742)
1. JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.
Liu Y; Zhang X; Wang J; Yang J; Tan WF
Acta Pharmacol Sin; 2015 Sep; 36(9):1099-106. PubMed ID: 26235742
[TBL] [Abstract][Full Text] [Related]
2. Twist1 and Snail link Hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters.
Kong Y; Peng Y; Liu Y; Xin H; Zhan X; Tan W
Stem Cells; 2015 Apr; 33(4):1063-74. PubMed ID: 25588661
[TBL] [Abstract][Full Text] [Related]
3. Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells.
Okada M; Shibuya K; Sato A; Seino S; Watanabe E; Suzuki S; Seino M; Kitanaka C
Oncol Rep; 2013 Oct; 30(4):1957-64. PubMed ID: 23912840
[TBL] [Abstract][Full Text] [Related]
4. Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.
Okada M; Shibuya K; Sato A; Seino S; Suzuki S; Seino M; Kitanaka C
Oncotarget; 2014 Jul; 5(13):5100-12. PubMed ID: 24947996
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest.
Kuntzen C; Sonuc N; De Toni EN; Opelz C; Mucha SR; Gerbes AL; Eichhorst ST
Cancer Res; 2005 Aug; 65(15):6780-8. PubMed ID: 16061660
[TBL] [Abstract][Full Text] [Related]
6. Roles of phosphorylated JNK in esophageal squamous cell carcinomas of Kazakh ethnic.
Qin X; Zheng S; Liu T; Liu Q; Liang M; Li X; Sheyhidin I; Lu X
Mol Carcinog; 2014 Jul; 53(7):526-36. PubMed ID: 23359384
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells.
Santini R; Vinci MC; Pandolfi S; Penachioni JY; Montagnani V; Olivito B; Gattai R; Pimpinelli N; Gerlini G; Borgognoni L; Stecca B
Stem Cells; 2012 Sep; 30(9):1808-18. PubMed ID: 22730244
[TBL] [Abstract][Full Text] [Related]
8. c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells.
Yoon CH; Kim MJ; Kim RK; Lim EJ; Choi KS; An S; Hwang SG; Kang SG; Suh Y; Park MJ; Lee SJ
Oncogene; 2012 Nov; 31(44):4655-66. PubMed ID: 22249269
[TBL] [Abstract][Full Text] [Related]
9. JNK1 and 2 play a negative role in reprogramming to pluripotent stem cells by suppressing Klf4 activity.
Yao K; Ki MO; Chen H; Cho YY; Kim SH; Yu DH; Lee SY; Lee KY; Bae K; Peng C; Lim DY; Bode AM; Dong Z
Stem Cell Res; 2014 Jan; 12(1):139-52. PubMed ID: 24211391
[TBL] [Abstract][Full Text] [Related]
10. Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties.
Xin H; Kong Y; Jiang X; Wang K; Qin X; Miao ZH; Zhu Y; Tan W
J Pharmacol Sci; 2013; 122(4):299-304. PubMed ID: 23903006
[TBL] [Abstract][Full Text] [Related]
11. JNK signaling maintains the mesenchymal properties of multi-drug resistant human epidermoid carcinoma KB cells through snail and twist1.
Zhan X; Feng X; Kong Y; Chen Y; Tan W
BMC Cancer; 2013 Apr; 13():180. PubMed ID: 23557251
[TBL] [Abstract][Full Text] [Related]
12. Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells.
Cui J; Wang Q; Wang J; Lv M; Zhu N; Li Y; Feng J; Shen B; Zhang J
Mol Cancer Ther; 2009 Dec; 8(12):3214-22. PubMed ID: 19996270
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.
Parra E; Ferreira J
Oncol Rep; 2013 Oct; 30(4):1936-42. PubMed ID: 23900581
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory pathway analysis using a high content screening platform.
Bertelsen M; Sanfridson A
Assay Drug Dev Technol; 2005 Jun; 3(3):261-71. PubMed ID: 15971988
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of c-Jun N-terminal kinase attenuates low shear stress-induced atherogenesis in apolipoprotein E-deficient mice.
Wang J; An FS; Zhang W; Gong L; Wei SJ; Qin WD; Wang XP; Zhao YX; Zhang Y; Zhang C; Zhang MX
Mol Med; 2011; 17(9-10):990-9. PubMed ID: 21629969
[TBL] [Abstract][Full Text] [Related]
16. JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis.
Alexaki VI; Javelaud D; Mauviel A
Pigment Cell Melanoma Res; 2008 Aug; 21(4):429-38. PubMed ID: 18541008
[TBL] [Abstract][Full Text] [Related]
17. Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells.
Seino M; Okada M; Shibuya K; Seino S; Suzuki S; Ohta T; Kurachi H; Kitanaka C
Anticancer Res; 2014 Sep; 34(9):4723-31. PubMed ID: 25202050
[TBL] [Abstract][Full Text] [Related]
18. JNK1 protects against glucolipotoxicity-mediated beta-cell apoptosis.
Prause M; Christensen DP; Billestrup N; Mandrup-Poulsen T
PLoS One; 2014; 9(1):e87067. PubMed ID: 24475223
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of sestrin 2 expression via JNK pathway activation contributes to autophagy induction in cancer cells.
Zhang XY; Wu XQ; Deng R; Sun T; Feng GK; Zhu XF
Cell Signal; 2013 Jan; 25(1):150-8. PubMed ID: 22982090
[TBL] [Abstract][Full Text] [Related]
20. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.
Yan F; Wang XM; Liu ZC; Pan C; Yuan SB; Ma QM
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):287-95. PubMed ID: 20525557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
